Nemec Sarah's Form 4 filing
Bolt Biotherapeutics, Inc.BOLT · filed Oct 24, 2025
- Accession no.
- 0001193125-25-250334
- Filed
- Oct 24, 2025
- Trade date
- Jun 6-Oct 22, 2025
- Filing delay
- 140 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market purchases total $686.25. It was filed 140 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Nemec SarahCIK 0002023538 | Officer (Senior VP, Finance and PAO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 6, 2025 | Common Stock | PPurchaseAcquired | +125 | $5.49 | +$686.25 | 943 | Direct | |
| Oct 22, 2025 | Common Stock | AGrant or awardAcquired | +23,000 | $0.00F2 | $0 | 23,943 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The shares represent restricted stock units that were received as an award, for no consideration. Each restricted stock unit represents the right to receive, at settlement, one share of common stock.
Referenced by the price of 1 transaction in Table I.